Login to Your Account

Evoke eyes finish line with phase III trial in gastroparesis

By Marie Powers
Staff Writer

Tuesday, April 22, 2014

Evoke Pharma Inc. enrolled the first patient in the phase III trial of EVK-001, its intranasal formulation of metoclopramide, to treat symptoms associated with acute and recurrent diabetic gastroparesis in women.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription